Carey K. Anders, MD, spoke about updated findings in the HER2-positive breast cancer space, based on data from 2023 SABCS.
ONCOLOGY® Companion, Volume 38, Supplement 6
During a Training Academy focused on first-line treatment use in non–small cell lung cancer, panelists discussed a patient case and how they would treat that patient in the setting.
A recent Training Academy focused on the advancements of treatment for patients with NSCLC EGFR mutations and exon 20 insertions.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab/Radiation Improves T Cell Infiltration in Early Breast Cancer
2
Resecting MRI-Detected Disease Doesn’t Improve Outcomes in Early-Stage BC
3
Nivolumab/AVD Receives FDA Priority Review in Classical Hodgkin Lymphoma
4
Sacituzumab Govitecan Does Not Meet Statistical Significance in HR+/HER2– mBC
5
